A5027608149- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease Diagnosis and Treatment
- RNA Interference and Gene Delivery
- Radiomics and Machine Learning in Medical Imaging
- Multiple and Secondary Primary Cancers
- Neuroendocrine Tumor Research Advances
- Peptidase Inhibition and Analysis
- Hip disorders and treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Advanced biosensing and bioanalysis techniques
- Nanoplatforms for cancer theranostics
- Sarcoma Diagnosis and Treatment
- Cancer Cells and Metastasis
- RNA modifications and cancer
- DNA and Nucleic Acid Chemistry
- Bone Tumor Diagnosis and Treatments
- Spinal Fractures and Fixation Techniques
- Cancer Mechanisms and Therapy
- Palliative Care and End-of-Life Issues
- Spine and Intervertebral Disc Pathology
Inserm
2011-2024
Hôpital de la Croix-Rousse
2012-2024
Université Clermont Auvergne
2013-2023
Centre Hospitalier Universitaire de Clermont-Ferrand
2013-2023
Imagerie Moléculaire et Stratégies Théranostiques
2019-2023
Clermont Université
2011-2023
Centre Hospitalier Universitaire de Tours
2021
Université de Tours
2021
Centre Jean Perrin
2011-2019
Hôpital Lyon Sud
2015
Plasma circulating cell-free (cf)DNA is of interest in oncology because it has been shown to contain tumour DNA and may thus be used as liquid biopsy. In nonsmall cell lung cancer (NSCLC), cfDNA quantification proposed for the monitoring follow-up patients. However, available studies are limited need confirmed by with larger sample sizes including patients who receive more homogenous treatments. Our objective was assess predictive prognostic value plasma concentration a large series NSCLC...
Resection surgery is the main treatment for non-small cell lung cancer (NSCLC). Postoperative complications and mortality are mostly linked to respiratory failure consecutive muscle overload.We aimed evaluate effect of preoperative endurance training (RMET) on capacity postoperative in patients undergoing NSCLC resection.Randomized controlled trial.French university hospital.Patients eligible resection.The group (T group) performed a 3-week RMET added usual chest physical therapy while...
Surgical resection plus adjuvant platinum-based chemotherapy is considered standard care for stage II to III non-small-cell lung cancer (NSCLC), but its efficacy limited, and it involves toxic risks, justifying patient-tailored treatment. Excision repair cross-complementation group 1 (ERCC1) was shown predict cisplatin-based response; EGFR mutations were predictive of epidermal growth factor receptor inhibition response.This prospective randomized phase trial enrolled 150 patients with...
// Jessica Garcia 1, 2, 3, 4 , Julien Forestier 5 Eric Dusserre Anne-Sophie Wozny 3 Florence Geiguer Patrick Merle 6, 7 Claire Tissot 8 Carole Ferraro-Peyret 9 Frederick S. Jones 10 Daniel L. Edelstein Valérie Cheynet 4, 11 Bardel 12, 18 Gaelle Vilchez Zhenyu Xu 13 Pierre Paul Bringuier Marc Barritault Karen Brengle-Pesce Marielle Guillet 14 Marion Chauvenet 15 Brigitte Manship 2 Marie Brevet 9, 16 Rodriguez-Lafrasse Hervieu Sébastien Couraud 16, 17 Thomas Walter and Léa...
Background: The IFCT-1603 trial evaluated atezolizumab in small cell lung cancer (SCLC). purpose of the present study was to determine whether circulating tumor DNA (ctDNA), prospectively collected at treatment initiation, associated with prognosis SCLC, and it identified patients who benefited from atezolizumab. Methods: 68 were included this study: 46 treated 22 conventional chemotherapy. Circulating extracted plasma NGS (Next Generation Sequencing) looked for mutations TP53, RB1, NOTCH1,...
Small cell lung cancer (SCLC) has a tendency towards recurrence and limited survival. Standard-of-care in 1st-line is platinum-etoposide chemotherapy plus atezolizumab or durvalumab,based on landmarkclinical trials.IFCT-1905 CLINATEZO nationwide, non-interventional, retrospectivestudy of patients with extensive-SCLC receivingatezolizumab as part French Early Access Program. Objectives were to analyse effectiveness,safetyand subsequent treatments.The population analyzed included 518 who...
Abstract The aim of this study was to test in vitro the efficacy TAC, an original G-quadruplex ligand, as a potential radiosensitizing agent for glioblastoma multiforme (GBM). Two human radioresistant telomerase-positive GBM cell lines (SF763 and SF767) were analyzed, with without TAC treatment, telomere length, proliferation, apoptosis, cell-cycle distribution, gene expression, cytogenetic aberrations, clonogenic survival assay, 53BP1 immunofluorescence staining, γH2AX phosphorylation. We...
Abstract Telomeres are nucleoprotein structures at the end of chromosomes which stabilize and protect them from nucleotidic degradation end-to-end fusions. The G-rich telomeric single-stranded DNA overhang can adopt a four-stranded G-quadruplex structure (G4). Stabilization G4 by binding small molecule ligands enhances radiosensitivity tumor cells this combined treatment represents novel anticancer approach. We studied effect platinum-derived G4-ligand, Pt-ctpy, in association with radiation...
ALK rearrangement and EGFR / KRAS mutations constitute the primary biomarkers tested to provide targeted or nontargeted therapies in advanced nonsmall cell lung cancer (NSCLC) patients. Our objective was assess cost-effectiveness of biomarker testing for NSCLC. Between 2013 2014, 843 treatment-naive patients were prospectively recruited at 19 French hospitals into a longitudinal observational cohort study. Two strategies compared, i.e. with “at least one status known” known”, addition “no...
Abstract Cell‐free plasma DNA (cfDNA) and mimicking circulating tumor cells (mCTCs) have demonstrated tremendous potential for molecular diagnosis of cancer been rapidly implemented in specific settings. However, widespread clinical adoption still faces some obstacles. The purpose was to compare the performance a BEAMing (beads, emulsion, amplification, magnetics) assay (OncoBEAM™‐epidermal growth factor receptor [ EGFR ] [Sysmex Inostics]) next‐generation sequencing (NGS; 56G Oncology panel...
Response Evaluation Criteria in Solid Tumors (RECIST) are widely used to assess the effect of chemotherapy patients with cancer. We hypothesised that change unidimensional tumour size handled as a continuous variable was more reliable than RECIST predicting overall survival (OS). The prospective Pharmacogenoscan study enrolled consecutive non-small-cell lung cancer (NSCLC) at any stage seen between 2005 and 2010 six hospitals France, given chemotherapy. After exclusion without or...
The IFCT-0504 phase II trial evaluated the efficacy of erlotinib versus carboplatin-paclitaxel (CP) as first-line treatment in 130 cases advanced lepidic-predominant adenocarcinoma (ADC).The primary objective study was efficacy, based on an end-point disease control at 16 weeks.The met, with a 35 (53%) out 66 patients treated CP and 25 (39.1%) 64 erlotinib. Median progression-free survival (PFS) for total population 3.6 months. rate did not differ between either therapeutic arms or...